JP7402218B2 - 安定な濃厚放射性核種錯体溶液 - Google Patents

安定な濃厚放射性核種錯体溶液 Download PDF

Info

Publication number
JP7402218B2
JP7402218B2 JP2021504167A JP2021504167A JP7402218B2 JP 7402218 B2 JP7402218 B2 JP 7402218B2 JP 2021504167 A JP2021504167 A JP 2021504167A JP 2021504167 A JP2021504167 A JP 2021504167A JP 7402218 B2 JP7402218 B2 JP 7402218B2
Authority
JP
Japan
Prior art keywords
solution
stabilizer
concentration
acid
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021504167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501313A (ja
Inventor
チッコ,ダニエラ
バーベイト,ドナート
パロ,フランチェスコ デ
フガッザ,ロレンツァ
マリアーニ,マウリツィオ
テソリエレ,ジョヴァンニ
ブランバーティ,クレメンタイン
Original Assignee
アドバンスド アクセラレーター アプリケーションズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7402218(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Application filed by アドバンスド アクセラレーター アプリケーションズ filed Critical アドバンスド アクセラレーター アプリケーションズ
Publication of JP2022501313A publication Critical patent/JP2022501313A/ja
Priority to JP2023085193A priority Critical patent/JP7796696B2/ja
Application granted granted Critical
Publication of JP7402218B2 publication Critical patent/JP7402218B2/ja
Priority to JP2025043874A priority patent/JP2025111424A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021504167A 2018-07-25 2018-09-25 安定な濃厚放射性核種錯体溶液 Active JP7402218B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023085193A JP7796696B2 (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液
JP2025043874A JP2025111424A (ja) 2018-07-25 2025-03-18 安定な濃厚放射性核種錯体溶液

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
IBPCT/IB2018/055575 2018-07-25
US16/045,484 2018-07-25
PCT/IB2018/057415 WO2020021322A1 (en) 2018-07-25 2018-09-25 Stable, concentrated radionuclide complex solutions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023085193A Division JP7796696B2 (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液

Publications (2)

Publication Number Publication Date
JP2022501313A JP2022501313A (ja) 2022-01-06
JP7402218B2 true JP7402218B2 (ja) 2023-12-20

Family

ID=63794577

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021504167A Active JP7402218B2 (ja) 2018-07-25 2018-09-25 安定な濃厚放射性核種錯体溶液
JP2023085193A Active JP7796696B2 (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液
JP2025043874A Pending JP2025111424A (ja) 2018-07-25 2025-03-18 安定な濃厚放射性核種錯体溶液

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023085193A Active JP7796696B2 (ja) 2018-07-25 2023-05-24 安定な濃厚放射性核種錯体溶液
JP2025043874A Pending JP2025111424A (ja) 2018-07-25 2025-03-18 安定な濃厚放射性核種錯体溶液

Country Status (23)

Country Link
EP (7) EP4545100B1 (cg-RX-API-DMAC7.html)
JP (3) JP7402218B2 (cg-RX-API-DMAC7.html)
KR (4) KR102865113B1 (cg-RX-API-DMAC7.html)
CN (5) CN112584875A (cg-RX-API-DMAC7.html)
AU (7) AU2018433575B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001148A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153630A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000506A2 (cg-RX-API-DMAC7.html)
DE (3) DE202018007006U1 (cg-RX-API-DMAC7.html)
DK (7) DK4640241T3 (cg-RX-API-DMAC7.html)
ES (6) ES3064434T3 (cg-RX-API-DMAC7.html)
FI (7) FI4545101T3 (cg-RX-API-DMAC7.html)
HR (6) HRP20260222T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072720T2 (cg-RX-API-DMAC7.html)
IL (5) IL280314B1 (cg-RX-API-DMAC7.html)
LT (7) LT4541381T (cg-RX-API-DMAC7.html)
MX (2) MX2021000805A (cg-RX-API-DMAC7.html)
PL (6) PL4545100T3 (cg-RX-API-DMAC7.html)
PT (7) PT4541381T (cg-RX-API-DMAC7.html)
RS (7) RS67729B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100645XA (cg-RX-API-DMAC7.html)
SI (6) SI4541381T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020021322A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006569A1 (en) * 2024-06-27 2026-01-02 Curium Us Llc 177lutetium-dota-tate formulations

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
US20250032652A1 (en) * 2021-11-30 2025-01-30 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CA3235923A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
WO2018081860A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528644A (ja) 2003-07-24 2006-12-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cancer Biotherapy and Radiopharmaceuticals, 2017.11, Vol.32, pp.266-273
J. Radioanal. Nucl. Chem., 2014, Vol.302, pp.889-894
J. Radioanal. Nucl. Chem., 2017.11, Vol.314, pp.2181-2188, <DOI 10.1007/s10967-017-5595-1>
Journal of Radioanalytical and Nuclear Chemistry, 2007, Vol.273, No.3, pp.689-694
Majalah Polimer Indonesia, Vol.19, No.1, 2016, pp.1-14
PRODUCTION and QUALITY CONTROL of 177Lu-DOTATATE [177Lu-DOTA-Tyr3]- OCTREOTATE: CLINICAL APPLICATION [retrieved on 2022/04/20], 2009,<https://inis.iaea.org/collection/NCLCollectionStore/_Public/43/004/43004240.pdf>

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006569A1 (en) * 2024-06-27 2026-01-02 Curium Us Llc 177lutetium-dota-tate formulations

Also Published As

Publication number Publication date
FI4541381T3 (fi) 2026-04-01
PT4545100T (pt) 2026-02-16
PL4541380T3 (pl) 2026-03-30
AU2022203683B2 (en) 2023-12-21
LT4541379T (lt) 2026-02-10
RS67667B1 (sr) 2026-02-27
ES3065583T3 (en) 2026-05-06
DK4545100T3 (da) 2026-02-23
EP4541380A3 (en) 2025-07-23
RS67755B1 (sr) 2026-03-31
EP4545100B1 (en) 2025-12-10
ES3064434T3 (en) 2026-04-24
ES3064589T3 (en) 2026-04-27
AU2025220852A1 (en) 2025-09-11
DK4545101T3 (da) 2026-03-02
IL280314A (en) 2021-03-25
DE202018007007U1 (de) 2025-11-13
KR20210035855A (ko) 2021-04-01
FI3826686T3 (fi) 2025-08-20
AU2026204487A1 (en) 2026-07-02
AU2025220852B2 (en) 2025-10-23
EP4541379B1 (en) 2025-11-19
WO2020021322A1 (en) 2020-01-30
CN121081692A (zh) 2025-12-09
EP4545101B1 (en) 2025-12-10
DK4541379T3 (da) 2026-02-02
IL319542A (en) 2025-05-01
IL326944A (en) 2026-05-01
LT4545101T (lt) 2026-03-10
RS68308B1 (en) 2026-07-31
JP2025111424A (ja) 2025-07-30
PT4640241T (pt) 2026-07-17
LT3826686T (lt) 2025-08-25
RS67754B1 (sr) 2026-03-31
FI4545101T3 (fi) 2026-02-24
MX2021000805A (es) 2021-05-12
HRP20260237T1 (hr) 2026-04-10
DK3826686T3 (da) 2025-08-25
EP4640241B1 (en) 2026-06-03
HRP20260179T1 (hr) 2026-04-10
EP4541380A2 (en) 2025-04-23
ES3067415T3 (en) 2026-05-21
CN120860272A (zh) 2025-10-31
EP4640241A2 (en) 2025-10-29
AU2022203683A1 (en) 2022-06-16
LT4541381T (lt) 2026-03-25
PT3826686T (pt) 2025-08-04
IL319542B2 (en) 2026-08-01
EP4545100A2 (en) 2025-04-30
PL4541379T3 (pl) 2026-03-23
DK4541381T3 (da) 2026-04-07
SG11202100645XA (en) 2021-02-25
KR102865113B1 (ko) 2025-09-26
DE202018007006U1 (de) 2025-11-13
FI4541379T3 (fi) 2026-02-17
JP2023117417A (ja) 2023-08-23
SI4541380T1 (sl) 2026-04-30
IL319542B1 (en) 2026-04-01
BR112021001148A2 (pt) 2021-04-20
EP3826686B1 (en) 2025-05-21
HRP20260338T1 (hr) 2026-04-10
EP4541379A2 (en) 2025-04-23
CN120860270A (zh) 2025-10-31
IL319541B1 (en) 2025-09-01
PL4541381T3 (pl) 2026-05-11
SI4545101T1 (sl) 2026-04-30
IL280314B1 (en) 2026-07-01
JP2022501313A (ja) 2022-01-06
KR20250017751A (ko) 2025-02-04
KR102932818B1 (ko) 2026-03-03
SI4541379T1 (sl) 2026-03-31
EP4640241A3 (en) 2025-12-10
AU2025204901A1 (en) 2025-07-17
AU2025202231B2 (en) 2026-05-14
MX2025012060A (es) 2025-11-03
CO2021000506A2 (es) 2021-04-19
FI4541380T3 (fi) 2026-03-02
PL3826686T3 (pl) 2025-09-22
ES3038413T3 (en) 2025-10-13
EP4541380B1 (en) 2025-12-10
EP4541381A3 (en) 2025-07-23
KR20240033296A (ko) 2024-03-12
PT4541381T (pt) 2026-03-17
EP4541379A3 (en) 2025-07-23
KR102643582B1 (ko) 2024-03-05
EP4541381B1 (en) 2026-02-04
IL313560A (en) 2024-08-01
DK4640241T3 (da) 2026-07-27
IL319541A (en) 2025-05-01
AU2024201217B2 (en) 2025-02-27
FI4640241T3 (fi) 2026-07-21
HRP20250912T1 (hr) 2025-09-26
PT4545101T (pt) 2026-02-24
IL319541B2 (en) 2026-01-01
PT4541380T (pt) 2026-02-24
HUE072720T2 (hu) 2025-12-28
AU2018433575B2 (en) 2022-07-07
CA3153630A1 (en) 2020-01-30
AU2025202231A1 (en) 2025-04-17
EP4541381A2 (en) 2025-04-23
SI3826686T1 (sl) 2025-09-30
EP4545101A3 (en) 2025-07-23
IL313560B1 (en) 2025-07-01
AU2024201217A1 (en) 2024-03-14
CN120860271A (zh) 2025-10-31
PL4545101T3 (pl) 2026-03-30
AU2018433575A1 (en) 2021-02-11
EP3826686A1 (en) 2021-06-02
EP4545100A3 (en) 2025-07-23
HRP20260100T1 (hr) 2026-04-10
LT4640241T (lt) 2026-07-27
DK4541380T3 (da) 2026-02-23
HRP20260222T1 (hr) 2026-03-27
LT4545100T (lt) 2026-02-25
DE202018006567U1 (de) 2021-04-01
CN112584875A (zh) 2021-03-30
PT4541379T (pt) 2026-01-29
PL4545100T3 (pl) 2026-03-30
KR20260030955A (ko) 2026-03-06
FI4545100T3 (fi) 2026-03-02
SI4541381T1 (sl) 2026-05-29
JP7796696B2 (ja) 2026-01-09
RS67729B1 (sr) 2026-03-31
LT4541380T (lt) 2026-03-10
EP4545101A2 (en) 2025-04-30
IL313560B2 (en) 2025-11-01
RS67864B1 (sr) 2026-04-30
SI4545100T1 (sl) 2026-03-31
AU2025204901B2 (en) 2025-09-18
RS67034B1 (sr) 2025-08-29
ES3063402T3 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
US12151003B2 (en) Stable, concentrated radionuclide complex solutions
US10596278B2 (en) Stable, concentrated radionuclide complex solutions
JP7796696B2 (ja) 安定な濃厚放射性核種錯体溶液
HK40119655A (en) Stable, concentrated radionuclide complex solutions

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20210416

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210720

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231208

R150 Certificate of patent or registration of utility model

Ref document number: 7402218

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150